9-me-bc
Small-molecule research compounds · 1 supplier · $0.04 per mg · 0 registered studies · 14 indexed papers
This page holds two records that were compiled separately. The research figures below come from the public registries named under each one, each read on the date printed beside it. The supplier prices at the foot were read on the suppliers own sites on the dates in that table. Nothing here was produced by this publication measuring anything.
Identity and computed properties
PubChem holds this compound as CID 164979, molecular formula C12H10N2, average mass 182.22 daltons and monoisotopic mass 182.0844 daltons, read on 2026-09-19. Those masses are computed from the deposited structure and were not measured on any material, so they are the expected value an identity check compares against rather than evidence about any vial.
The title that record carries for the CID is 9-Methyl-beta-carboline. Its synonym list runs to 41 entries. Among them: 9-methyl-9H-pyrido[3,4-b]indole and 9-Methyl-9H-pyrido(3,4-b)indole.
Receptors the literature describes
No published paper this search reached describes a receptor this compound acts at.
The registered trial record
No study naming this compound is registered on clinicaltrials.gov. The intervention term searched on 2026-09-19 was 9-methyl-beta-carboline.
Registry counts measure registration, not knowledge.
The publication record
PubMed answered 14 records for the term 9-methyl-beta-carboline on 2026-09-19. None of the 14 carries a clinical-trial publication type. 2 carry the publication type Review, which is other people reading the rest.
PubMed counts measure indexing, so work in venues it does not index is invisible to this figure. The term that produced it is printed above so it can be run again.
Regulatory status
A Drugs@FDA query on 2026-09-19 returned no application record for any of these 6 searches:
- openfda.generic_name:"9-methyl-beta-carboline"
- openfda.substance_name:"9-methyl-beta-carboline"
- openfda.brand_name:"9-methyl-beta-carboline"
- openfda.generic_name:"9-methylnorharman"
- openfda.substance_name:"9-methylnorharman"
- openfda.brand_name:"9-methylnorharman"
Those are results for the 6 searches printed above, and nothing wider. A compound holding an approved application under a name none of those searches covers would not answer any of them, and no dated note of which names were checked, and why those are the ones to check, is recorded here.
Findings, as published reports recorded them
This block was compiled and no finding from a named publication was reached.
Adverse events, as published reports recorded them
This block was compiled and no adverse event from a named publication was reached.
Spontaneous report databases are not used on this page. A count of reports carries no denominator, so it cannot be read as a rate and is not printed as one.
Who it is not given to
No doctor prescribes this. There is no approved product under this name on the Food and Drug Administration record, read 2026-09-19, so there is no label naming who must avoid it and why.
The other place that answer usually comes from is a trial, which has to write down who it will not enrol. No registered study was found for this compound on 2026-09-19, so there is no exclusion list either.
Read this as missing information, not as a clear record. Nobody has published who is at risk, which is not the same as nobody being at risk.
What has not been published
- None of the 14 indexed records carries a clinical-trial publication type, so the human lane of this record is empty.
- No study naming this compound is registered on clinicaltrials.gov.
Where a line above says nothing has been compiled here, that is a gap in this publication's record. Where it says nothing is indexed or registered, that is a gap in the public record.
Every row is a price read on that supplier's own site, divided by the milligrams it buys. Cheapest first, which is not a ranking of quality: the columns beside the rate show what this publication could confirm about the evidence behind it. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Vendor comparison
| Per mg | Price | Supplier | Certificate checkable | Caution on record | What the figure is |
|---|---|---|---|---|---|
| $0.04per mg | $100.0050mg × 50 vials | 303 Peptidesrecord → | not checkable | The catalog, every product page, the certificate page and the homepage itself redirect to an account wall. Only the refund policy serves directly, so nothing can be checked before registering. | capsulesread 2026-08-24 |
Read between 2026-08-24 and 2026-08-24. Prices move and these were read once.
Sources
Registered study counts, phases, lead sponsors and first-submitted dates: the clinicaltrials.gov public API, one intervention search on the term printed above, read 2026-09-19. Indexed paper counts and publication types: PubMed, the term printed above and that term narrowed by publication type, read 2026-09-19. Formula and computed mass: PubChem, the CID printed above, read 2026-09-19. Application status: the Food and Drug Administration Drugs@FDA database through the agency public endpoint, read 2026-09-19.
The dates in the paragraph above are the dates those fetches ran, stamped in UTC. The dates in the list below are the dates a person read each record. The same record can carry both, a day apart, when a fetch ran after midnight UTC.
- PubChem compound record, CID 164979 read 2026-09-19